{
    "clinical_study": {
        "@rank": "30369", 
        "arm_group": {
            "arm_group_label": "CD8 DLI", 
            "arm_group_type": "Experimental", 
            "description": "CD8 depleted DLI (Depleted Donor Lymphocyte Infusions)"
        }, 
        "brief_summary": {
            "textblock": "Primary Objectives:\n\n      To evaluate response rates of acute or chronic Graft-versus-host disease (GVHD) following\n      CD8 depleted DLI (Depleted Donor Lymphocyte Infusions) in patients with Chronic\n      myelomonocytic leukemia (CMML), chronic lymphoid leukemia (CLL), Non-Hodgkin's lymphoma\n      (NLM), Multiple Myeloma (MM) and Hodgkin's Lymphoma (HD).\n\n      Secondary Objectives:\n\n        -  To evaluate safety and treatment related mortality after CD8 depleted DLI.\n\n        -  To evaluate the time to onset of GVHD following DLI and response to GVHD treatment.\n\n        -  To evaluate the incidence and timing of pancytopenia following DLI.\n\n        -  To evaluate disease-free survival, overall survival and relapse rates in three cohorts\n           of patients; early relapse CML, late relapse CML and lymphoproliferative disorders (HD,\n           CLL, NHL and MM).\n\n        -  To evaluate the need and efficacy of second or subsequent CD8 depleted donor lymphocyte\n           infusions.\n\n        -  To evaluate the number of apheresis procedures needed to collect appropriate doses of\n           CD4+ cells."
        }, 
        "brief_title": "CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation", 
        "completion_date": {
            "#text": "December 2002", 
            "@type": "Actual"
        }, 
        "condition": [
            "Chronic Myelogenous Leukemia", 
            "Multiple Myeloma", 
            "Non Hodgkin's Lymphoma", 
            "Hodgkin's Disease", 
            "Chronic Lymphocytic Leukemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hodgkin Disease", 
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid", 
                "Leukemia, Myeloid", 
                "Leukemia, Myelogenous, Chronic, BCR-ABL Positive", 
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin", 
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "-  Patients of any age who have previously undergone allogeneic hematopoietic\n             transplantation and have evidence of donor cell engraftment (>20% donor cell within\n             three months of study entry)\n\n          -  Expected survival >4 weeks\n\n          -  CML patients with molecular, cytogenetic or hematologic relapse following allogeneic\n             transplantation\n\n               1. Molecular relapse- patients are eligible if bcr/abl is detectable at any time\n                  after day 180 post-allogeneic transplantation or if a negative bcr/abl PCR test\n                  was documented post-transplantation and the bcr/abl test is now positive by\n                  consecutive PCR determinations at least 4 weeks apart.\n\n               2. Cytogenetic relapse-patients are eligible if standard cytogenetics demonstrate\n                  >10% t (9,22) positive cells greater than 60 days after myeloablative\n                  transplantation or 10% t (9,22) positive cells greater than 100 days after\n                  nonmyeloablative transplantation.\n\n          -  CML patients with accelerated phase or blast crisis following allogeneic\n             transplantation\n\n          -  Patients with CLL, NHL, MM, or HD who have evidence of disease relapse or persistent\n             disease at 60 days post-allo BMT and/or:\n\n               1. MM- patients with a rising M-protein is detectable at 180 days post-transplant\n\n               2. NHL - patients with molecular evidence of disease (bcl-2, t (4,11), etc.) at 180\n                  days post transplant\n\n               3. CLL, NHL or HD - patients with clear cut evidence of tumor growth at any time\n                  post-transplant are eligible\n\n          -  Patients undergoing an HLA -identical or 5/6 antigen match transplant from a related\n             or unrelated donor\n\n          -  Patient's original donor must be available for lymphocyte donation\n\n          -  There must be no evidence of active acute or graft-versus-host disease and patients\n             should be off all immunosuppressive agents for, at least, two weeks prior to DLI.\n             Patients on stable dose of methylprednisolone (<16 mg/d) without evidence of active\n             GVHD are also eligible.\n\n          -  Patients must have a Zubrod PS<2 (see appendix 7), Cr<2.5, bilirubin <3, and\n             transaminases (SGPT, SGOT) <4x normal\n\n          -  Patient must be able to sign informed consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "3", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 5, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00038818", 
            "org_study_id": "ID00-335"
        }, 
        "intervention": {
            "arm_group_label": "CD8 DLI", 
            "intervention_name": "CD8 Depleted Donor Lymphocyte", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "CML", 
            "MM", 
            "NHL", 
            "HD", 
            "CLL", 
            "CD8 Depleted", 
            "Donor Lymphocyte"
        ], 
        "lastchanged_date": "August 22, 2012", 
        "link": {
            "description": "UT MD Anderson Cancer Center website", 
            "url": "http://www.mdanderson.org"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Houston", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "77030"
                }, 
                "name": "UT MD Anderson Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "CD8 Depleted Donor Lymphocyte Infusions for Patients With Relapse Or Residual Disease Following Allogeneic Stem Cell Transplantation", 
        "overall_official": {
            "affiliation": "UT MD Anderson Cancer Center", 
            "last_name": "Richard Champlin, MD, BS", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2002", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Patient Response Rates of Acute or Chronic GVHD", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00038818"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "M.D. Anderson Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "Eligix", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "M.D. Anderson Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2001", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012", 
        "why_stopped": "Low accrual."
    }, 
    "geocoordinates": {
        "UT MD Anderson Cancer Center": "29.76 -95.369"
    }
}